Private Client Services LLC Raises Holdings in Eli Lilly and Company $LLY

Private Client Services LLC increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 7.3% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,247 shares of the company’s stock after purchasing an additional 85 shares during the quarter. Private Client Services LLC’s holdings in Eli Lilly and Company were worth $972,000 as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. WestEnd Advisors LLC increased its position in shares of Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after purchasing an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC purchased a new stake in shares of Eli Lilly and Company during the first quarter worth approximately $27,000. Citizens National Bank Trust Department increased its position in shares of Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after purchasing an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. purchased a new stake in shares of Eli Lilly and Company during the first quarter worth approximately $40,000. Finally, TD Capital Management LLC boosted its stake in Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after buying an additional 31 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Eli Lilly and Company

In other news, EVP Daniel Skovronsky bought 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average price of $634.40 per share, with a total value of $634,400.00. Following the purchase, the executive vice president owned 137,660 shares in the company, valued at approximately $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director J Erik Fyrwald bought 1,565 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the purchase, the director owned 74,578 shares in the company, valued at $47,903,686.74. This represents a 2.14% increase in their position. The disclosure for this purchase can be found here. Insiders bought 4,514 shares of company stock worth $2,894,841 in the last 90 days. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Down 0.2%

Shares of LLY opened at $754.90 on Friday. The firm has a market cap of $714.48 billion, a P/E ratio of 49.34, a price-to-earnings-growth ratio of 1.05 and a beta of 0.47. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $942.35. The company’s 50-day moving average price is $741.03 and its 200 day moving average price is $777.36. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company’s revenue was up 37.6% on a year-over-year basis. During the same period in the previous year, the firm earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 10th. Investors of record on Friday, August 15th were issued a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.8%. The ex-dividend date was Friday, August 15th. Eli Lilly and Company’s payout ratio is 39.22%.

Analysts Set New Price Targets

A number of research firms have weighed in on LLY. Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 30th. Guggenheim lowered their price objective on Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating on the stock in a research note on Wednesday, August 13th. Erste Group Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating in a research note on Thursday, June 5th. Deutsche Bank Aktiengesellschaft lowered their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research note on Monday, August 11th. Finally, Hsbc Global Res raised Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 27th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $941.35.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.